Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy

Authors

Marie‐Claude Bourgeois‐Daigneault

Published

January 3, 2018

Abstract

Maraba virus treatment before surgery for triple-negative breast cancer promotes antitumor immunity.

Supporters

Support the authors with ResearchCoin

Journal

Science Translational Medicine

Topics

DOI

10.1126/scitranslmed.aao1641

Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy

Authors

Marie‐Claude Bourgeois‐Daigneault

Published

January 3, 2018

Abstract

Maraba virus treatment before surgery for triple-negative breast cancer promotes antitumor immunity.

Supporters

Support the authors with ResearchCoin

Journal

Science Translational Medicine

Topics

DOI

10.1126/scitranslmed.aao1641

Paper

Paper

Paper

Paper

Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy

Abstract

Supporters

Journal

Topics

DOI

Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy

Abstract

Supporters

Journal

Topics

DOI